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REVIEW ARTICLE OPEN
Fighting bioﬁlms with lantibiotics and other groups of
bacteriocins
Harsh Mathur1,2, Des Field 2,3, Mary C. Rea1,2, Paul D. Cotter1,2, Colin Hill2,3 and R. Paul Ross2,4
Bioﬁlms are sessile communities of bacteria typically embedded in an extracellular polymeric matrix. Bacterial cells embedded in
bioﬁlms are inherently recalcitrant to antimicrobials, compared to cells existing in a planktonic state, and are notoriously difﬁcult to
eradicate once formed. Avenues to tackle bioﬁlms thus far have largely focussed on attempting to disrupt the initial stages of
bioﬁlm formation, including adhesion and maturation of the bioﬁlm. Such an approach is advantageous as the concentrations
required to inhibit formation of bioﬁlms are generally much lower than removing a fully established bioﬁlm. The crisis of antibiotic
resistance in clinical settings worldwide has been further exacerbated by the ability of certain pathogenic bacteria to form bioﬁlms.
Perhaps the most notorious bioﬁlm formers described from a clinical viewpoint have been methicillin-resistant Staphylococcus
aureus (MRSA), Staphylococcus epidermidis, Pseudomonas aeruginosa, Gardnerella vaginalis and Streptococcus mutans, the latter of
which is found in oral bioﬁlms. Due to the dearth of novel antibiotics in recent decades, compounded by the increasing rate of
emergence of resistance amongst pathogens with a propensity for bioﬁlm formation, solutions are urgently required to mitigate
these crises. Bacteriocins are a class of antimicrobial peptides, which are ribosomally synthesised and often are more potent than
their antibiotic counterparts. Here, we review a selection of studies conducted with bacteriocins with the ultimate objective of
inhibiting bioﬁlms. Overall, a deeper understanding of the precise means by which a bioﬁlm forms on a substrate as well as insights
into the mechanisms by which bacteriocins inhibit bioﬁlms is warranted.
npj Bioﬁlms and Microbiomes  (2018) 4:9 ; doi:10.1038/s41522-018-0053-6
INTRODUCTION
Bioﬁlms are composed of cells in a sessile state found in a
polymeric matrix, and can be attached to both biotic and abiotic
substrates.1–4 Bioﬁlms have been known to contribute to physical
and chemical protection as well as protection from antimicro-
bials.2 In clinical settings, the survival of bioﬁlms on medical
devices and hospital equipment permits certain pathogens to
easily infect patients. Once infected, pathogen-associated bioﬁlms
can evade human host immune defences and are frequently
associated with persistent infections, often resistant to antibiotic
therapy.5 The stages involved in the formation of a bioﬁlm are
quite complex and several comprehensive reviews have already
described the bioﬁlm growth cycle, whereby bacteria adhere to a
substrate, followed by maturation of the bioﬁlm and subsequent
release of clusters of cells from the matrix of the bioﬁlm (see
reviews by Garrett et al. and Flemming & Wingender).6,7 The
concentrations of antibiotics needed to eradicate a bioﬁlm can
often range from 100 to 1000× minimum inhibitory concentration
(MIC) of that needed to kill planktonic cells.5,8,9 Aside from
antimicrobial resistance, bacteria present in a bioﬁlm are also
resistant to various physicochemical stresses, enabling bioﬁlms to
persist in even the harshest of conditions. In the food industry,
bioﬁlms have the ability to cause food-borne disease outbreaks.
Furthermore, inefﬁcient cleaning regimes may be a contributing
factor in the spread of resistance in hospital environments10. Thus,
there has been a growing emphasis on attempting to prevent the
initial stages of bioﬁlm formation, in lieu of targeting fully formed
bioﬁlms.11 Thus far, attempts have been made to target adhesion,
quorum sensing and dispersion of bioﬁlms, each of which are
critical steps in the formation of a fully established bioﬁlm.12 A
recent comprehensive review described the efﬁcacy of antibiotics
in combination with other antimicrobial peptides and essential
oils, as well as the effectiveness of bioﬁlm-degrading enzymes,
quorum sensing inhibitors and nano particles as potential anti-
bioﬁlm agents.13
Due to the widespread resistance of bioﬁlms to conventional
antibiotics, one alternative avenue to tackle this problem is to
harness bacteriocins as antimicrobials either independently or in
combination with existing proven antimicrobials, with a view to
targeting bioﬁlms. Bacteriocins are antimicrobial peptides pro-
duced by bacteria typically 2–10 kDa in size, generally targeting
closely related bacteria, and are ribosomally synthesised in
nature.14,15 They are broadly classiﬁed into two main groups,
namely class I (post-translationally modiﬁed) and class II
(unmodiﬁed) bacteriocins. By far the most extensively studied
subgroup is the lantibiotics belonging to class I bacteriocins. These
are characterised by the unusual amino acids, dehydroalanine and
dehydrobutyrine, as a result of the dehydration of serine and
threonine residues, as well as the presence of lanthionine (Lan)
and β-methyllanthionine (MeLan) intramolecular bridges.16,17
Unsurprisingly, the vast majority of bacteriocins which have been
studied thus far with a view to targeting bioﬁlms are lantibiotics.
The various applications of bacteriocins, including food
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preservation, health beneﬁts, as well as anti-bioﬁlm activity were
already addressed in a recent review.18
Critically, unlike antibiotics, the ribosomally-synthesised nature
of bacteriocins renders them one of the most amenable agents to
manipulate or bioengineer to target speciﬁc pathogens and
bioﬁlm formers. Indeed, several studies have reported enhanced
bioactivity and/or physicochemical properties of bacteriocins
including ameliorated diffusion properties and stability in different
pH conditions, traits which have been strategically bioengi-
neered.19–27 Perhaps the most thoroughly studied bacteriocin
has been the lantibiotic nisin. This lantibiotic has already been
reported to be effective at permeating bioﬁlms and the
opportunity exists to improve this characteristic by seeking
derivatives which have an enhanced ability to diffuse through
the various complex strata in a bioﬁlm.28–31 Such increased
diffusion properties would not only make them more potent
against bioﬁlms but also effective in various food systems,
targeting potential food-borne bioﬁlm formers such as Listeria
monocytogenes. In addition, the advantages of generating
bioengineered derivatives of bacteriocins with augmented bioac-
tivity can also reduce costs associated with targeting bioﬁlms, as
lower concentrations of the relevant peptide(s) will be needed,
relative to the wild-type parental peptide(s).32 Furthermore, as the
majority of bacteriocins are marginally cationic in nature, they
have a tendency to be naturally attracted to anionic surfaces.
Impregnation of such anionic surfaces with these cationic
bacteriocins can also potentially render such peptides useful
against bioﬁlms forming on such a surface. In addition,
bacteriocins, and especially those produced by lactic acid bacteria
generally exhibit relatively low levels of cytotoxicity towards
human and animal tissues. Indeed, the non-toxic nature of nisin
has been highlighted on a number of occasions,33,34 while
Murinda et al. also reported that the bacteriocins nisin, pediocin
and colicin E6 displayed little or no cytotoxicity towards Vero
Monkey Kidney cells.35 Rare exceptions do exist however, such as
the Enterococcus-associated cytolysin, which has demonstrated
cytotoxicity.36
In this review, we summarise the ﬁndings from some key recent
studies which have utilised bacteriocins as a means to target
bioﬁlms. Due to their potency and efﬁcacy against bioﬁlms which
is comparable to conventional antibiotics, bacteriocins could be
harnessed as alternative and/or adjunctive therapeutic options to
combat bioﬁlms. The use of bacteriocins as adjuncts to antibiotics
also has the potential to somewhat curtail the widespread
problem of antibiotic resistance.
LANTIBIOTICS AGAINST BIOFILMS
The biological value of several bacteriocins is further enhanced by
their activity against bioﬁlms, which are notoriously challenging to
eradicate using conventional antibiotics. The lantibiotics are by far
the most extensively studied subclass of bacteriocins and thus it is
no surprise that the majority of studies with bacteriocins targeting
bioﬁlms have predominantly involved this group. Several studies
have also explored combinations of lantibiotics with other
bacteriocins or stressors with a view to either preventing the
formation of bioﬁlms and/or eradicating existing bioﬁlms. In one
such study, Mataraci and Dosler investigated the potency of
several antibiotics combined with nisin against MRSA ATCC43300
planktonic cells and bioﬁlms.12 S. aureus is a pathogen causing
several skin infections as well as other systemic infections and
several authors have already described the importance of bioﬁlms
in its pathogenicity.37–44 Synergistic interactions were found with
antibiotic–nisin combinations, in terms of fractional inhibitory
concentration determinations, whereas additive effects were
obtained against planktonic cells of MRSA in the study by
Mataraci and Dosler. Furthermore, antibiotic–nisin combinations
were effective at preventing bioﬁlm formation at 1× MIC.12 In
contrast, however, bioﬁlm-associated bacteria were highly resis-
tant to antibiotics or nisin–antibiotic combinations. In a follow-up
study by the same group, it was determined using time-kill assays
that nisin acted synergistically with the antibiotics ciproﬂoxacin/
daptomycin against MRSA bioﬁlms.45 Okuda and co-workers also
assessed the antimicrobial potencies of the lantibiotics nisin and
nukacin ISK-1, as well as the bacteriocin lacticin Q against bioﬁlms
of MRSA.46 Nukacin ISK-1 is a class II lantibiotic47,48 while lacticin Q
is a broad spectrum unmodiﬁed bacteriocin and thus has been
categorised into a new family of class II bacteriocins.49,50 It was
shown that while the glycopeptide antibiotic vancomycin was
ineffective against MRSA bioﬁlms, lacticin Q and nisin exhibited
bactericidal activity against the bioﬁlm, with nisin displaying more
potent activity compared to lacticin Q.46 While the lantibiotic
nukacin ISK-1 failed to inhibit MRSA bioﬁlms, it did possess strong
activity against planktonic cells. Overall, the study unveiled that
the bacteriocins elicited pore formation and a consequent efﬂux
of ATP from the bioﬁlms and that this is an important mechanism
of action in targeting MRSA bioﬁlms.46
Sub-lethal concentrations of the lantibiotic nisin and the class II
bacteriocin bovicin HC5 have also been shown to disrupt S. aureus
adhering to polystyrene.51 Adhesion to abiotic surfaces such as
polystyrene is a key step in the formation of bioﬁlms. Interestingly,
in the study by Pimentel-Filho et al. application of nisin and
bovicin rendered the surfaces more hydrophilic and alterations in
the free energy of adhesion between the polystyrene surfaces and
bacterial cells prevented adhesion to the surface.51 Thus,
modiﬁcations in the hydrophobicity of abiotic surfaces as well as
bacterial cell surfaces triggered by bacteriocins can hinder this
critical adhesion stage in bioﬁlm formation. Importantly, it was
determined that nisin and bovicin also had an impact on the
transcription of certain genes in S. aureus, primarily affecting clfB,
fmnbA and icaD, which are involved in bioﬁlm formation. In
another study, the impact of lysozyme and nisin on the bioﬁlm
forming ability of 25 S. aureus strains was evaluated and the
authors found that the presence of nisin at 1× MIC inhibited the
formation of bioﬁlms, while sub-lethal concentrations failed to
have any inhibitory effect.52
With regards to other Staphylococcus bioﬁlm formers, one study
demonstrated the efﬁcacy of the lantibiotic gallidermin against S.
epidermidis as well as against S. aureus bioﬁlms.53 S. epidermidis
exists as a commensal organism on the skin but has also been
implicated in causing several nosocomial infections.54 Indeed, S.
epidermidis has been described as the most common causative
agent of medical device-associated infections and its ability to
form bioﬁlms is a key contributing factor in its pathogenic
potential.55 Encouragingly, gallidermin was shown to prevent the
growth of the Staphylococcus strains as well as inhibiting the
formation of bioﬁlms.53 However, the killing effect of gallidermin
was diminished against 1 day-old and 5 day-old bioﬁlms.
Worryingly, approximately 0.1 to 1.0% of cells exposed to the
lantibiotic were persister cells which survived gallidermin treat-
ment.53 Persister cells are cells which reside in a dormant state in
microbial communities and typically exhibit resistance to anti-
microbials. Indeed, it has been suggested that the presence of
persister cells may be the predominant reason for chronic
infections displaying antibiotic resistance.56,57 Such persister cells
may also be an important part of bioﬁlms and likely contribute to
the antibiotic-resistant properties of bioﬁlms.58,59. With regards to
S. epidermidis bioﬁlms, a study by Davison et al. demonstrated that
50 µg/ml nisin was able to permeate through the bioﬁlm cell
clusters in 4 min, when assessed by using continuous ﬂow models
and confocal laser scanning microscopy.28 Unlike other antimi-
crobials used in the study, the lantibiotic elicited a quick and
steady loss of green ﬂuorescence from the bioﬁlm, suggesting
that permeation was highly effective across all the strata of the
bioﬁlm. During transit through the complex matrix of the bioﬁlm,
the lantibiotic was able to cause a loss of cell membrane integrity
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and consequently elicit a loss of viability of cells within the bioﬁlm.
Signiﬁcantly, penetration of nisin through bioﬁlms and planktonic
cells occurred at a largely similar rate. It was also reassuring that a
subpopulation of cells exhibiting decreased sensitivity to the
lantibiotic was not seen. Overall, the authors concluded that nisin
was effective at killing the cells in the bioﬁlm but not effective at
removing the existing bioﬁlm.28 Recent studies have also reported
the activity of nisin and bioengineered variants thereof against
other Staphylococcus bioﬁlms. Indeed, the nisin variant I4V was
particularly effective at inhibiting the formation of Staphylococcus
pseudintermedius DSM21284 bioﬁlms and decreasing the biomass
of established bioﬁlms (Fig. 1).31,32 This canine pathogen is
implicated in skin and wound infections and resistance to the
antibiotic methicillin is common. Signiﬁcantly, one study eval-
uated the ability of S. pseudintermedius isolated from dogs in
forming bioﬁlms and the study reported that a staggering 96% of
the strains assessed were able to form bioﬁlms.60 As expected,
there was no correlation found between methicillin sensitivity or
resistance and the ability to form bioﬁlms.60
Food-borne pathogens have also been associated with the
formation of bioﬁlms, permitting them to persist in a viable state
in food production environments.61,62 Although primarily found in
a planktonic state, L. monocytogenes also has the ability to form
bioﬁlms under certain conditions.63–67 Consequently, several
groups have evaluated the efﬁcacy of lantibiotics against bioﬁlms
of L. monocytogenes. In one such study, the efﬁcacy of nisin in
combination with the essential oil cinnamaldehyde, and the food
additive citric acid, at targeting bioﬁlms of L. monocytogenes strain
F2635 was reported. More speciﬁcally, 0.1 μg/ml of the bioengi-
neered nisin derivative, M21A, independently and in combination
with 175 μg/ml citric acid or 35 μg/ml cinnamaldehyde was
particularly potent against F2635 bioﬁlms, more so than
combinations involving wild-type nisin A.68 In a separate study,
the resistance properties of 4 and 11 day-old L. monocytogenes
bioﬁlms were assessed by measuring lethal dose 90 values of
nisin, as well as assessment of bioﬁlms via microscopy.69
Interestingly, the authors described that L. monocytogenes strain
4032 which formed bioﬁlms on both polypropylene and stainless
steel (SS) assumed a ‘cloud-type’ structure which was thought to
contribute to resistance to nisin as well as other biocides.
Importantly however, such resistance was associated with mature
bioﬁlms and not early stage bioﬁlms or planktonic cells.69 The anti-
bioﬁlm activities of several bacteriocins including the two-peptide
lantibiotic lichenicidin and the single peptide lantibiotics nisin Z
and subtilomycin, were assessed in a recent study, showing that
the bacteriocins were effective at inhibiting formation of L.
monocytogenes bioﬁlms and decreasing the viability of bioﬁlms
already formed.70 A separate study demonstrated that 4000 IU/ml
nisin elicited a 57% reduction in L. monocytogenes bioﬁlm
formation, an 87% reduction in Salmonella enteriditis and a 30%
decrease in S. aureus bioﬁlm formation.71 The efﬁcacy of high
hydrostatic pressure (HHP) in combination with nisin in low pH
conditions on targeting L. monocytogenes bioﬁlms has also been
evaluated.72 Inactivation of cells in the L. monocytogenes bioﬁlm
was apparent subsequent to HHP treatment when cells were
treated in tryptic soy broth (TSB) pH5 supplemented with nisin.
Furthermore, it was found that the presence of nisin in TSB at pH5
elicited a 5-log cfu/ml decrease in cell numbers and the cells
became shorter in size.72
Studies investigating the potency of lantibiotics with a view to
targeting bioﬁlms formed by Gram negatives have also been
explored. For instance, a recent study reported that nisin-
polymyxin combinations were effective at inhibiting the formation
of Pseudomonas aeruginosa bioﬁlms (Fig. 2).73 P. aeruginosa is
classiﬁed as an opportunistic Gram negative pathogen and is
known to colonise and form bioﬁlms in the lungs of cystic ﬁbrosis
patients.8,74,75 Field and co-workers demonstrated that the dose of
polymyxin needed to prevent formation of P. aeruginosa bioﬁlms
was reduced in the presence of nisin. Nisin and related lantibiotics
in general exhibit poor activity against Gram negative bacteria,
primarily due to the presence of the outer membrane, which
prevents nisin accessing its target, lipid II, in the cytoplasmic
membrane.76–80 It is plausible that by binding the lipid A
component of lipopolysaccharide, and thereby permeabilizing
the outer membrane of P. aeruginosa, the transit of nisin to its
target lipid II in the cytoplasmic membrane is facilitated by
polymyxin, resulting in the apparent synergistic effect observed by
Field et al.73. Indeed, previous studies had also demonstrated the
synergistic effects of nisin in combination with polymyxins against
the Gram negatives P. aeruginosa and E. coli. 81–83 A synergistic
interaction of this nature could be a potential avenue to curtail the
nephrotoxicity associated with polymyxins when treating P.
aeruginosa infections clinically.
LANTIBIOTICS AGAINST ORAL BIOFILMS
Perhaps the most common bioﬁlm found in the human body is
dental plaque in the oral cavity and is associated with the
causation of dental caries and periodontal disease.84–88 Thus,
several investigators have examined various means to minimise
the negative effects associated with dental plaque bioﬁlms. In
particular, Strep. mutans is a key organism implicated in the
formation of dental bioﬁlms and is the primary causative agent of
caries.89 In contrast, oral bioﬁlms containing Streptococcus
sanguinis may be associated with good oral health as periodontal
disease has been linked with decreased Strep. sanguinis colonisa-
tion.90 Several investigators have attempted to target Strep.
Fig. 1 Bioﬁlms treated with nisin assessed by microscopy: Assessment of S. pseudintermedius DK729 (top triangle) and S. pseudintermedius
DSM21284 (bottom triangle) bioﬁlms (magniﬁcation 1000×) after 24 h treatment with 16× MIC of nisin A (Wt) and nisin I4V peptides. (Adapted
from Field et al. 2015c 31 under the terms of the Creative Commons Attribution License)
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mutans by various means91–93 and have evaluated the effects of
numerous reagents on Strep. mutans bioﬁlms.94
With respect to the use of lantibiotics against oral bioﬁlms, Tong
and co-workers examined the anti-bioﬁlm activities of nisin,
independently and in combination with free amino acids in
targeting Strep. mutans bioﬁlms.95 The results of crystal violet
bioﬁlm assays indicated that mixtures of either the L or D-
enantiomers of Glu, Asp or Cys in combination with nisin could
ameliorate the potency of nisin against bioﬁlms of Strep. mutans.95
Indeed, free amino acids are an essential component of
peptidoglycan and serve to regulate and disassemble bioﬁlms.95
The potency of nisin in inhibiting insoluble glucan-bioﬁlm
synthesis by Strep. mutans 10449 was evaluated in another
relatively recent study.96 It was found that 100 pmol of pure nisin
prevented Strep. mutans 10449 from forming an insoluble glucan
bioﬁlm, after 1 h of cultivation. In contrast, a four-fold lower
concentration of encapsulated nisin in liposomes was needed to
have the same inhibitory effect on bioﬁlm formation, after 2 h of
cultivation. This is most likely due to the slower release of the
peptide from nisin-liposomes, leading to prolonged anti-bioﬁlm
activity, compared to that of non-encapsulated naked nisin, whose
inhibitory activity was relatively short-lived. Encouragingly,
30 pmol nisin in an encapsulated liposome form was effective at
preventing bioﬁlm formation by strain 10449 for a period of 6 h, in
contrast to 30 pmol of nisin that was not encapsulated, which
failed to maintain inhibitory activity for the same duration of time.
Signiﬁcantly, the results from the study highlight the effectiveness
of encapsulated nisin in liposomes for a prolonged release of the
peptide.96 An interesting study by Corbin et al. investigated the
penetrative capabilities of nisin with a view to targeting dental
bioﬁlms. The application of nisin elicited a loss of green
ﬂuorescence, which was most notable along the cell cluster edge,
relative to the centre of the cluster. However, nisin failed to cause
complete eradication of the bioﬁlm.97 With regards to other
lantibiotics targeting oral bioﬁlms, one study evaluated the
efﬁcacy of the two-component lantibiotic, lacticin 3147, in
inhibiting the formation of bioﬁlms by S. mutans and it was
found that 2× MIC (6.3 μM) of lacticin 3147 was effective at
disrupting bioﬁlm formation by Strep. mutans. However, the
lantibiotic was not as effective against bioﬁlms which were already
4 h old.98
With respect to other bioﬁlm-forming organisms in the oral
cavity, Tong and co-workers conducted a separate study in which
they assessed the effect of adding nisin to MTAD (mixture of
tetracycline, acid and doxycycline) and its anti-bioﬁlm activity
against Enterococcus faecalis isolates.99 In contrast to bioﬁlms of
the oral pathogen Strep. mutans, E. faecalis bioﬁlms contain
reduced levels of extracellular polysaccharides and higher
quantities of extracellular DNA, resulting in lower impedance to
penetration by antimicrobials.100 Importantly, it was found that
nisin in combination with doxycycline successfully inhibited E.
faecalis bioﬁlms whereas MTAD on its own was ineffective against
such bioﬁlms. This successful combination could be harnessed as
an antimicrobial/irrigant following root canal treatments to
prevent post-operative E. faecalis infections. In this regard, it
should be noted that aside from being implicated in the formation
of oral bioﬁlms, E. faecalis is an important nosocomial pathogen
and has exhibited resistance to various classes of antibiotics.
Indeed, Enterococcus species are implicated in endocarditis,
catheter-related infections, urinary tract infections and infections
associated with surgical wounds.101–103 Encouragingly, a recent
study by Kajwadkar et al. revealed that nisin ZP, which is a
naturally occurring variant of nisin A, independently and in
combination with sodium hypochlorite was potent against E.
faecalis bioﬁlms and planktonic cells. Exposure of the bioﬁlm to
nisin ZP at concentrations >10 µg/ml for 10 mins were effective at
decreasing the thickness and bio-volume of the bioﬁlm, while
combinations of nisin ZP with low concentrations of sodium
hypochlorite were also found to be effective at reducing the
biomass of the bioﬁlm.104
Actinomyces viscosus is another member of the oral cavity and is
frequently found as a bioﬁlm in periodontal pockets.87,105–107 It
has also been implicated in endocarditis, similar to E. faecalis.108
Balto et al. investigated the efﬁcacy of the dental irrigant MTAD in
combination with nisin on A. viscosus and E. faecalis bioﬁlms on
membrane ﬁlter discs. Unfortunately however, there was no
difference in the viability of the A. viscosus and E. faecalis bioﬁlms
when treated with MTADN (MTAD with added nisin) and 5.25%
sodium hypochlorite.109 Finally, a recent study demonstrated that
the bacteriocin EntV produced by a strain of E. faecalis, prevents
bioﬁlm formation by the yeast Candida albicans.110 C. albicans
bioﬁlms are frequently associated with oral and vaginal
thrush.111,112 The anti-bioﬁlm activity of EntV is mediated via the
disruption of hyphal formation, which is essential for C. albicans
bioﬁlm formation. Signiﬁcantly, the study showed that the 68-
amino acid peptide, EntV, prevented development of C. albicans
bioﬁlms (which were recalcitrant to several antifungals) on solid
surfaces in various media conditions.110 Thus, this bacteriocin
Fig. 2 Anti-bioﬁlm activity of nisin and polymyxins against P. aeruginosa: Inhibition of bioﬁlm formation of P. aeruginosa PA-01 a) in the
presence of nisin (1/3× MIC), colistin (1/2×, 1/5× MIC) and combinations thereof and b) in the presence of nisin (1/4× MIC) and polymyxin B (1/
2×, 1/5× MIC) and combinations thereof, when assessed in microtiter plates and subjected to crystal violet (CV) staining for the detection of
bioﬁlm formation. (Adapted from Field et al. 2016b 73 under the terms of the Creative Commons Attribution License)
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could have tremendous potential as a therapeutic agent for both
oral and vaginal thrush.
A summary of studies involving lantibiotics utilised in an effort
to target bioﬁlms is found in Table 1.
ANTI-BIOFILM ACTIVITY OF OTHER GROUPS OF BACTERIOCINS
While the majority of studies with bacteriocins used to target
bioﬁlms have used lantibiotics, other groups of bacteriocins have
also been investigated. Recently, Chopra et al. reported the
discovery of a novel bacteriocin, sonorensin, which possessed
potent anti-bioﬁlm activity. Sonorensin belongs to the hetero-
cycloanthracin subclass of bacteriocins.113,114 This novel bacter-
iocin exhibited potent activity against S. aureus bioﬁlms and it was
unveiled that the inhibition of bioﬁlm growth could be ascribed to
increased membrane permeability.113 The antimicrobial effects of
enterocin AS-48 (a class IIc circular bacteriocin) both indepen-
dently and in combination with several biocides against three
MRSA and three methicillin-sensitive S. aureus (MSSA) strains was
also assessed in a separate study by Caballero Gómez and co-
workers.115–117 Caballero Gómez and co-workers found that the
anti-bioﬁlm activity of the biocides triclosan, benzalkonium
chloride and polyhexamethylene guanidium chloride were highly
effective in combination with 50 μg/ml of AS-48 against S. aureus
bioﬁlms in storage conditions.115 Another study demonstrated the
efﬁcacy of the class IIb bacteriocins enterocin DD93 and DD28
against MRSA bioﬁlms. The enterocins were effective at inhibiting
the formation of MRSA-1 bioﬁlms on glass and SS surfaces when
combined with the antibiotics kanamycin or erythromycin.118
Finally, a novel circular sactibiotic, hyicin 4244, produced by
Staphylococcus hyicus 4244, has been shown to exhibit anti-bioﬁlm
activity against fourteen Staphylococcus strains which were the
causative agents of either bovine or human mastitis.119 Signiﬁ-
cantly, the sactibiotic decreased the bioﬁlm forming capacity of
two of these strains as well as decreasing CFU (colony forming
unit) counts. Furthermore, the sactibiotic elicited decreases in
viability and growth of sessile cells in already established bioﬁlms.
Thus, not only was it effective at inhibiting bioﬁlm formation, it
was also able to traverse existing bioﬁlms.
With respect to the inhibition of L. monocytogenes bioﬁlms,
Caballero Gómez et al. in another study found that enterocin AS-
48 was effective at targeting planktonic cells but the organism was
Table 1. Activity of the lantibiotic group of bacteriocins against bioﬁlms
Bacteriocin(s) Bioﬁlm former Effects Reference
Nisin in combination with
antibiotics
MRSA Nisin-antibiotic combinations prevented bioﬁlm formation 12
Nisin with ciproﬂoxacin/
daptomycin
MRSA Synergy between nisin and ciproﬂoxacin/daptomycin against
bioﬁlm
45
Nisin, lacticin Q, nukacin ISK-1 MRSA Nisin and lacticin Q potent against bioﬁlm, causing pore
formation, efﬂux of ATP from bioﬁlm. No anti-bioﬁlm activity for
nukacin ISK-1
46
Nisin, bovicin HC5 S. aureus Reduced adhesion to polystyrene. Reduced expression of genes
involved in bioﬁlm formation
51
Nisin and lysozyme 25 S. aureus strains 1× MIC nisin prevented bioﬁlm formation 52
Gallidermin S. aureus, S. epidermidis Prevention of bioﬁlm formation. Persister cells survived 53
Nisin S. epidermidis Loss of green ﬂuorescence from bioﬁlm, loss of viability and
membrane integrity
28
Nisin I4V S. pseudintermedius I4V inhibited formation and reduced biomass of bioﬁlms 31
Nisin I4V S. pseudintermedius I4V potent against DSM21284 bioﬁlms 32
Nisin M21A with citric acid or
cinnamaldehyde
L. monocytogenes F2635 Nisin combined with essential oils effective against bioﬁlm 68
Nisin L. monocytogenes 4032 Mature bioﬁlms on stainless steel and polypropylene recalcitrant
to nisin
69
Nisin S. aureus, L. monocytogenes,
Salmonella enteritidis
4000 IU/ml particularly effective against Salmonella enteritidis and
L. monocytogenes bioﬁlm formation
71
Nisin at low pH with high
hydrostatic pressure (HHP)
L. monocytogenes Nisin at low pH combined with HHP effective against bioﬁlms 72
Nisin and polymyxin P. aeruginosa Inhibition of bioﬁlm formation. Dose of polymyxin required
lowered
73
Nisin in combination with Glu, Asp,
Cys
Strep. mutans Improved potency against Strep. mutans bioﬁlms with nisin-
amino acid combinations
95
Nisin Strep. mutans 10449 Inhibition of glucan bioﬁlm synthesis. Encapsulated nisin most
effective
96
Nisin Oral bioﬁlm Loss of green ﬂuorescence across bioﬁlm cell clusters 97
Lacticin 3147 Strep. mutans 2× MIC disrupted formation of bioﬁlms. Ineffective against 4-h-
old bioﬁlms
98
Nisin and MTAD E. faecalis Nisin and doxycycline inhibited E. faecalis bioﬁlms 99
NisinZP and sodium hypochlorite E. faecalis Thickness and bio-volume of bioﬁlm decreased 104
Nisin and MTAD E. faecalis, A. viscosus No effect on bioﬁlms 109
Subtilomycin, lichenicidin and
nisinZ
L. monocytogenes Prevention of bioﬁlm formation 70
EntV C. albicans Prevention of C. albicans bioﬁlm formation 110
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insensitive to 10 μg/ml AS-48 when cells were present in a sessile
state.120 Thus, responses to the bacteriocins were markedly
altered between L. monocytogenes cells existing in a planktonic
state or sessile state. Interestingly, the authors found that in the
sessile state, protein synthesis is prioritised in lieu of carbohydrate
metabolism when cells are exposed to bacteriocins. Furthermore,
stress response proteins such as GroEL and DnaK were over-
expressed by bioﬁlm cells upon exposure to the bacteriocin and
some of these overexpressed proteins actually contribute to
adhesion of the bioﬁlm to surfaces,120 suggesting that exposure to
sub-lethal concentrations of bacteriocins may in fact trigger
bioﬁlm formation in some instances. In contrast, an earlier study
by the same group showed that AS-48 was effective when
combined with several biocides against L. monocytogenes cells
present in a sessile state.121 While high concentrations of AS-48
(50 μg/ml) on its own were required to inhibit L. monocytogenes
bioﬁlms attached to polystyrene plates, there was a marked
improvement in the inactivation of bioﬁlms when AS-48 was
applied in combination with the biocides used in the study, with
the exception of the sanitisers P3 topax 66 and P3 oxonia
solutions. In addition, pre-treatment of polystyrene plates with
0.5–25 µg/ml AS-48 led to a reduction in adherence and
consequent formation of L. monocytogenes bioﬁlms.121 Finally,
an interesting study recently reported the efﬁcacy of the class II
unmodiﬁed bacteriocin licheniocin 50.2 against bioﬁlms of L.
monocytogenes as well as against coagulase-negative Staphylo-
coccus (CoNS) bioﬁlms.122 CoNS are important clinically and
amongst the most common CoNS pathogens are S. epidermidis,
S. haemolyticus, S. saprophyticus and S. lugdunensis.123–126 Cirkovic
and co-workers tested the efﬁcacy of the two new bacteriocins
against twelve L. monocytogenes and eight CoNS strains. It was
noted that low concentrations of licheniocin 50.2 were effective at
preventing CoNS bioﬁlm formation while the crude extract from
strain BGBUI-4 successfully prevented formation of bioﬁlms by L.
monocytogenes. In addition, 100 AU/ml and 200 AU/ml of the
bacteriocins were effective at diminishing the biomass of 1 day-
old L. monocytogenes and CoNS bioﬁlms.122 Despite these
promising outcomes, caution must be exercised when utilising
crude extracts, as the apparent anti-bioﬁlm activity observed
might not solely be due to the presence of bacteriocins but
additional compounds present in the extract as well.
With respect to targeting bioﬁlms formed by Gram negatives,
combinations of enterocin DD14, nisin and the antibiotic colistin
proved successful at removing E. coli CIP54127 bioﬁlms in one
study.127 Enterocin DD14 is an unusual two-peptide class IIb
bacteriocin devoid of a leader sequence.128 The E. coli strain
CIP54127 has previously been reported to exhibit resistance to
disinfectants including oxidising agents, phenolic derivatives and
cationic or amphoteric surfactants, chieﬂy due to its bioﬁlm-
forming ability.129 Signiﬁcantly, in addition to strain CIP54127,
enterocin DD14, nisin and colistin combinations were also
effective against bioﬁlms of E. coli 184 (mcr-1+) and E. coli (mcr-
1−), which are known to be resistant to colistin. Turovskiy et al.
investigated the efﬁcacy of the sactibiotic bacteriocin subtilosin,
lauramide arginine ethyl ester (LAE) and Ɛ-poly-L-lysine against
bioﬁlms of the Gram variable pathogen Gardnerella vaginalis,
using ATP viability, resazurin assays and plate counts.130 This
pathogen is associated with recurrent bacterial vaginosis and its
bioﬁlm forming ability facilitates its colonisation and contributes
to antibiotic resistance.131,132 While subtilosin exhibited antimi-
crobial activity against G. vaginalis bioﬁlms, it was noteworthy that
the study demonstrated that resazurin assays and ATP viability
assays led to an underestimation of the bactericidal effect of
certain antimicrobials, highlighting the limitations and the
variability associated with certain viability assays.130 In a follow-
up study, Algburi et al. determined that sub-inhibitory concentra-
tions of subtilosin disrupts quorum sensing in G. vaginalis bioﬁlms,
as well as in bioﬁlms formed by Gram negative bacteria.133 The
peptide was shown to elicit a decrease in the production of
autoinducer-2 (AI-2) within G. vaginalis bioﬁlms and a similar
reduction in the production of voilacein by a Gram negative
reporter Chromobacterium voilaceum strain. Interestingly however,
while sub-MIC levels of subtilosin were able to reduce the
formation of L. monocytogenes bioﬁlms, a concomitant decrease in
AI-2 production was not observed, indicating that mechanisms
other than quorum sensing inhibition may be responsible for
subtilosin’s inhibitory activity against L. monocytogenes
bioﬁlms.133
Finally, it has been shown that the class IIb bacteriocin
plantaricin A in the presence of Lactobacillus sanfranciscensis
DPMMA174 and Lactobacillus plantarum DPPMA20 actually
facilitated the formation of bioﬁlms by Lb. plantarum DC400 (ref.
134). An increase in bioﬁlm formation can perhaps be beneﬁcial in
some cases whereby a potential ‘probiotic’ bioﬁlm former such as
Lb. plantarum can confer protection against bioﬁlms involving
other potentially pathogenic strains.
APPLICATION OF BACTERIOCINS ONTO ABIOTIC SURFACES
WITH A VIEW TO INHIBITING BIOFILMS
Since established bioﬁlms are notoriously difﬁcult to control,
perhaps a more logical approach is to apply bacteriocins onto
certain abiotic surfaces, to prevent the formation of target bioﬁlms
on such susceptible surfaces. This strategy was utilised in a recent
study by Al-Seraih et al., whereby the authors described the
efﬁcacy of enterocin B3A-B3B, as well as nisin, against L.
monocytogenes bioﬁlms.135 Enterocin B3A-B3B is a class IIb
bacteriocin, highly similar in sequence to MR10A-MR10B. The
enterocin disrupted the formation of L. monocytogenes 162
bioﬁlms on SS. Furthermore, the study showed that application
of 1 mg/ml or 16 mg/ml nisin onto the surface of SS elicited a 2-
log cfu/ml reduction in cell numbers and consequently inhibited
the formation of bioﬁlms of L. monocytogenes 162 and 162R (nisin-
resistant derivative), respectively. In addition, B3A-B3B combined
with nisin proved to be effective as it led to a decrease in MIC
needed to impede the growth of this pathogen in either bioﬁlms
or in a planktonic state.135 In another study, Nostro and co-
workers assessed the efﬁcacy of poly-ethylene-co-vinyl-acetate
(EVA) ﬁlms incorporated with nisin at inhibiting the bioﬁlm-
forming capabilities of S. epidermidis ATCC35984, S. aureus 815 and
L. monocytogenes ATCC7644 (ref. 136). A combination of techni-
ques including measurements of bioﬁlm biomass, live/dead
staining and ﬂuorescence microscopy was used to assess anti-
bioﬁlm properties and it was established that EVA14 (nisin) ﬁlms
were more effective at diminishing the bioﬁlm-forming abilities of
S. epidermidis, and less effective against S. aureus and L.
monocytogenes strains. These ﬁndings were validated by ﬂuores-
cence microscopy which demonstrated markedly reduced bioﬁlm
formation on EVA14 ﬁlms incorporated with nisin. In contrast,
EVA28 (nisin) ﬁlms failed to show any anti-bioﬁlm activity.136 A
separate study of this nature demonstrated that immobilised nisin
with poly-ethylene glycol utilised as a linker, potentiated the anti-
bioﬁlm activity of multi-walled carbon nanotubes (MWNT).137
Indeed, this composite of nisin immobilised-MWNTs displayed a
higher degree of antimicrobial activity against S. aureus, Bacillus
subtilis, P. aeruginosa and E. coli. Signiﬁcantly, this composite was
effective at inhibiting the formation of bioﬁlms either in
suspension or on a deposited ﬁlm. Encouragingly, the anti-
bioﬁlm properties of the nisin-MWNT deposit ﬁlm was approxi-
mately 100-fold greater than MWNT deposit ﬁlms without nisin.137
A similar separate study also evaluated the efﬁcacy of a MWNT
sheet which was coated with nisin (MWCNT), in inhibiting the
formation of bioﬁlms by Bacillus anthracis.138 B. anthracis is a
notorious pathogen and is the causative agent of pulmonary,
cutaneous and gastrointestinal anthrax. It has also been reported
to be a strong bioﬁlm former and such bioﬁlms of B. anthracis
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exhibit resistance to several antibiotics.139 Signiﬁcantly, Dong et al.
noted that B. anthracis bioﬁlm formation was inhibited by up to
94.6% with MWCNT sheets coated with nisin, relative to sheets
which were uncoated, as it is likely that nisin prevented adhesion
of the bioﬁlm. The activity of nisin combined with 2, 3-
dihydroxybenzoic acid (DHBA) in nanoﬁbers and its ability to
inhibit MRSA bioﬁlm formation was also explored in a relatively
recent study.140 The nanoﬁbers which contained DHBA in
combination with nisin were particularly effective, eliciting an
88% reduction in formation of MRSA bioﬁlms after 24 h of
exposure. Finally, in another study, nisin bound to SS surfaces was
shown to decrease adhesion and consequently reduce the
formation of bioﬁlms of Listeria ivanovii on the surface.141
ACTIVITY OF UNCHARACTERISED BACTERIOCINS AND CRUDE
EXTRACTS AGAINST BIOFILMS
There have been a number of studies conducted whereby a
bacteriocinogenic strain was utilised in an effort to target bioﬁlms.
However, in many instances, the bacteriocin was not fully
characterised at the time of the study. In some of these studies
below, the uncharacterised bacteriocin was puriﬁed or semi-
puriﬁed, prior to investigation, while in others, crude extracts of
the uncharacterised bacteriocins or co-cultures of the bacterioci-
nogenic strain with the target bioﬁlm-forming organism were
utilised. It must be noted that the presence of other compounds in
crude extracts of bacteriocins may be additional confounding
factors, when evaluating anti-bioﬁlm activity, as several of these
compounds could possibly contribute to the apparent inhibitory
activity.
With respect to investigations utilising puriﬁed or semi-puriﬁed
bacteriocins, Ming et al. showed that bacteriocins produced by Lb.
plantarum, which were puriﬁed by ammonium sulphate precipita-
tion, caused an inhibition of bioﬁlms of Strep. sanguinis.142 A
separate study reported the discovery of a novel bacteriocin
produced by the Gram negative, Citrobacter freundii, which
possesses potent anti-bioﬁlm activity. This novel bacteriocin was
effective against both planktonic cells and bioﬁlms of Citrobacter
species, E. coli and Klebsiella pneumoniae.143 K. pneumoniae is an
important nosocomial opportunistic Gram negative pathogen,
implicated in infections of the lung, as well as being able to form
bioﬁlms on abiotic surfaces, such as urinary catheters.144,145 The
puriﬁed bacteriocin from C. freundii, once expressed in a
heterologous E. coli host, also possessed potent activity against
bioﬁlms of K. pneumoniae, E. coli and Citrobacter species.143
Bioﬁlms of the Gram negative pathogen Serratia marcescens were
also targeted using puriﬁed and partially-puriﬁed bacteriocins
produced by Lb. plantarum ATCC 8014 and Lactobacillus
acidophilus ATCC4356 respectively.146 Ser. marcescens has a
propensity to form strong bioﬁlms, largely determined by the
availability of nutrients in the environment. It has been associated
with negative transfusion reactions caused by contaminated
platelet concentrates and has also been implicated in urinary
tract infections in hospitalised patients, exhibiting resistance to
certain antibiotics.147,148
With regards to studies involving co-culture of bacteriocino-
genic strains along with the target bioﬁlm species, and/or
involving crude extracts containing uncharacterised bacteriocins,
one such study showed that the bacteriocin produced by
Lactobacillus sakei CRL1862 was able to inhibit L. monocytogenes
bioﬁlm formation, and this anti-bioﬁlm forming activity was more
potent on polytetraﬂuoroethylene (PFTE) surfaces, relative to SS
surfaces.149 In addition, co-culture of the bacteriocinogenic Lb.
sakei strain along with the L. monocytogenes target elicited a
decrease by 4.52 and 5.54-log on SS and PFTE surfaces
respectively.149 Another study evaluated the efﬁcacy of nisin as
well as a bacteriocinogenic Enterococcus faecium strain on the
ability of L. monocytogenes to form bioﬁlms on SS coupons and in
Brain Heart Infusion broth.150 Interestingly, co-culture of L.
monocytogenes and the bacteriocinogenic E. faecium strain
prevented L. monocytogenes adherence and bioﬁlm formation
for up to 2 days. The presence of nisin also led to a decrease in
bacterial growth up to 4.6-log cfu/cm2 on SS coupons, in
comparison to untreated L. monocytogenes cultures. Worryingly,
however, nisin failed to kill the cells in the bioﬁlm and a new
bioﬁlm layer was apparent in cultures exposed to nisin. Thus,
while the presence of nisin led to a decrease in L. monocytogenes
growth, the co-culture of L. monocytogenes with the bacteriocino-
genic E. faecium strain was the most effective option for
diminishing the formation of L. monocytogenes bioﬁlms.150 A
study by Camargo et al. investigated the efﬁcacy of different
bacteriocins against bioﬁlms of L. monocytogenes. Interestingly, it
was noted that the bacteriocin-containing cell free supernatants
(CFS) from Lactobacillus curvatus ET31 effectively reduced the
formation of L. monocytogenes bioﬁlms (initial stages of bioﬁlm
formation). However, the CFS was ineffective after the bioﬁlm had
already formed. The CFS was also tested in combination with the
chelating agent ethylene diaminetetraacetic acid (EDTA). While
the bacteriocin and the EDTA independently were ineffective
against L. monocytogenes bioﬁlms which had already formed, the
combination was effective at reducing the viability of established
bioﬁlms, whilst not fully eliminating the bioﬁlms.151 The anti-
bioﬁlm activity of bacteriocins produced by Lb. fermentum 97
against bioﬁlms of several enterotoxigenic enterobacteria, S.
epidermidis and C. albicans has also been demonstrated.152 C.
albicans, the causative agent of candidiasis, is a nosocomial fungal
pathogen and has the ability to form relatively strong bioﬁlms,
particularly in the oral cavity.153 Indeed, candidiasis has been
described as the most prevalent fungal infection in humans.154
Finally, Lin et al. found that Strep. mutans UA159 bioﬁlm formation
was inhibited through the production of bacteriocin-like polypep-
tides produced by Lactobacillus strains.155
A summary of studies involving other non-lantibiotic groups of
bacteriocins and uncharacterised bacteriocins used to target
bioﬁlms is found in Table 2.
CONCLUSIONS
Due to the dearth of novel antibiotics in recent years, and the on-
going crisis of antimicrobial resistance, bacteriocins may yet prove
to be invaluable in clinical settings against bioﬁlm producers. It is
noteworthy that thus far, only the derivative of the lantibiotic
deoxyactagardine B, NVB302, has undergone clinical trials and in
general bacteriocins have failed to gain traction as alternative/
adjunct therapeutic options in the clinic.156,157 Despite the paucity
of clinical trials conducted with bacteriocins however, some key
in vivo studies have assessed the efﬁcacy of bacteriocin producers
as potential probiotics. One example of a bacteriocin producer
which could be harnessed as a probiotic is Lactobacillus salivarius
UCC118, which produces the bacteriocin Abp118. A murine trial
showed the ability of this bacteriocin producer to successfully
colonise mice infected with L. monocytogenes.158 In a follow-up
study, it was discovered that bacteriocin gene expression was up-
regulated when UCC118 adhered to epithelial cells, most likely
being mediated by an induction peptide present in high
concentrations.159 Other such examples include a study which
showed that colicin-producing E. coli strains survived for a longer
duration of time in the large intestine of mice treated with
streptomycin, compared to non-colicin producing derivatives,
indicating that bacteriocin production could be considered a
probiotic trait.160 For comprehensive reviews highlighting the
potential role of bacteriocin production as a probiotic trait, the
reader is referred to Hegarty et al.161 and Dobson et al.162
With respect to evaluating the effectiveness of antimicrobials
against bioﬁlms, several different types of assays including a
variety of ﬂuorescence microscopy techniques, cell viability and
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metabolic activity-based assays, and microtitre-based dye staining
methods to measure bioﬁlm biomass, are used to measure anti-
bioﬁlm activity (for a comprehensive review, see Azeredo et al.).163
While some of these assays quantify the removal of the pre-
formed established bioﬁlm biomass, other assays merely quantify
the reduction in the ability to form bioﬁlms due to the activity of
the antimicrobial in question against planktonic cells. Perhaps a
combination of some of these techniques is warranted to gain
comprehensive insights into the inhibitory activity of the anti-
bioﬁlm agents being investigated, as each of these assays presents
its own advantages as well as limitations.
A number of studies have identiﬁed effective
bacteriocin–antimicrobial combinations with regards to targeting
bioﬁlms comprised of pathogens. It is conceivable that effective
combinations of this nature will also attenuate the likelihood of
development of antimicrobial resistance. Amongst the key
advantages of bacteriocins is that oftentimes, they can be more
potent than antibiotics in targeting planktonic cells and/or
bioﬁlms. Furthermore, the bioengineering of lantibiotics and
indeed other groups of bacteriocins can unleash a plethora of
derivatives with ameliorated bioactivity and other favourable
physicochemical properties, many of which may be useful against
bioﬁlms. Indeed, advances in molecular biology techniques and
high throughput facilities have led to the creation of a greater
number of banks of bioengineered bacteriocins in the last decade
or so.19,20,24 Critically, it has also been shown that the most
thoroughly studied bacteriocin, nisin, is not broken down or
trapped in the matrix within a bioﬁlm, thus facilitating its further
penetration into the inner depths of the bioﬁlm.28 It must be
noted however, that the lantibiotic may well be cleaved due to the
presence of proteases in vivo, especially if administered orally.
Nonetheless, it was particularly noteworthy from the study by
Davison et al. that although the molecular weight of nisin is
approximately ten-fold higher than quaternary ammonium
compounds (QAC), the bacteriocin was able to penetrate through
to the depths of the bioﬁlm cell cluster quicker than QACs. It is
plausible that synthetic antimicrobials which possess enhanced
diffusion properties with a structure similar to nisin could also be
developed in order to traverse the stratiﬁed layers of bioﬁlms.
Furthermore, it may also be possible to bioengineer other groups
of bacteriocins to improve their diffusion properties with a view to
penetrating bioﬁlms. Indeed, optimisation of the aqueous diffu-
sion coefﬁcient of a bacteriocin peptide is likely to be critical for
effective transit across the strata of the bioﬁlm.28
However, perhaps a better option to circumvent the antimicro-
bial resistance that is inherent in bioﬁlms is to seek synergistic
combinations of bacteriocins with other antimicrobials that
possess proven anti-bioﬁlm properties. Any such synergistic
combinations are likely to retard the development of resistance
to either of the antimicrobials used in combination. Furthermore,
effective synergistic combinations between bacteriocins and
antibiotics are likely to reduce the concentrations of expensive
antibiotics required to target bioﬁlms. While this can be
advantageous in certain instances due to the fact that some
antibiotics such as the polymyxins can trigger undesired side
effects such as nephrotoxicity at higher concentrations in clinical
Table 2. Activity of other groups of bacteriocins and uncharacterised bacteriocins against bioﬁlms
Bacteriocin(s) Bioﬁlm former Effects Reference
Sonorensin S. aureus Strong activity against S. aureus bioﬁlms and
inhibition of bioﬁlm formation
113
Enterocin AS-48 with benzalkonium chloride,
polyhexamethylene guanidium chloride and
triclosan
MRSA and MSSA 50 µg/ml enterocin with biocides effective against
MRSA bioﬁlms
115
Enterocin DD93, DD28 with erythromycin or
kanamycin
MRSA Combinations prevented bioﬁlm formation 118
Enterocin AS-48 L. monocytogenes 10 µg/ml AS-48 ineffective against sessile cells 120
Enterocin AS-48 with biocides L. monocytogenes 50 µg/ml AS-48 needed to inhibit bioﬁlm forming
on polystyrene. More effective in combination
with biocides
121
Licheniocin 50.2 L. monocytogenes, coagulase
negative-staphylococci
Prevented formation of bioﬁlms 122
Nisin, enterocin DD14, colistin combination E. coli CIP54127, E. coli 184 (mcr-
1+) and E. coli (mcr-1−)
Removal of bioﬁlm 127
Subtilosin, LAE, ε-poly-L-lysine G. vaginalis Effective against bioﬁlm 130
Hyicin 4244 Staphylococcus strains Reduced formation of bioﬁlms. Reduced viability
and growth of sessile cells
119
Plantaricin A Lb. plantarum DC400 Increased bioﬁlm formation when plantaricin A
was combined with Lb. sanfranciscensis and Lb.
plantarum strains
134
Various bacteriocins with EDTA. Lb. curvatus ET31
CFS.
L. monocytogenes CFS potent at preventing bioﬁlm but ineffective
against formed bioﬁlms.
151
Bacteriocin from Lb. sakei CRL1862 L. monocytogenes Bioﬁlms targeted on PFTE, SS surface 149
Nisin and bacteriocin from E. faecium L. monocytogenes Co-culture prevented bioﬁlm formation 150
Bacteriocin from Lb. fermentum 97 S. epidermidis, C. albicans,
enterotoxigenic enterobacteria
Effective against S. epidermidis bioﬁlms 152
Lactobacillus strains producing bacteriocins Strep. mutans Prevention of bioﬁlm formation 155
Lb. plantarum producing bacteriocins Strep. sanguinis Anti-bioﬁlm activity against Strep. sanguinis 142
Bacteriocin from Citrobacter freundii Citrobacter, K. pneumoniae, E. coli Potent against bioﬁlms 143
Bacteriocins from Lb. plantarum ATCC8014 and Lb.
acidophilus ATCC4356
Ser. marcescens Bioﬁlm inhibited 146
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situations,164 it must be highlighted that the presence of sub-
inhibitory concentrations of antibiotics may actually trigger the
development of antibiotic resistance, as has been described
previously.165–168
Despite numerous potential advantages associated with using
bacteriocins, they are by no means panaceas to target recalcitrant
bioﬁlms and several bottlenecks do exist with bacteriocins
targeting bioﬁlms as well. Bioﬁlms are notoriously difﬁcult to
remove and high concentrations of antimicrobials are required to
inhibit them once they’re formed. As is the case with many
antimicrobials, bacteriocins in general seem to be more effective
at inhibiting the formation of bioﬁlms but exhibit reduced efﬁcacy
at targeting bioﬁlms which are already formed. Another funda-
mental bottleneck with bacteriocins is the relatively low produc-
tion of peptide(s) made by natural producers and the potential
expense associated with puriﬁcation of any such low-yielding
peptide(s). However, advances in screening as well as optimisation
of puriﬁcation technologies have the potential to somewhat
curtail these limitations. It is also possible that the production of a
bacteriocin in a heterologous host can increase the yield of the
peptide(s) produced, thereby reducing the costs involved in
puriﬁcation. Due to the proteinaceous nature of bacteriocins, the
secretion of proteases by bioﬁlms also has the potential to render
bacteriocins and indeed other antimicrobial peptides ineffective
and one study has already described proteases released by P.
aeruginosa bioﬁlms upon exposure to the antibiotic ciproﬂox-
acin.169 However, it may be possible to mitigate this potential
proteolysis via bioengineering of protease-resistant derivatives of
bacteriocins. Other obstacles include a lack of detailed insights
into the mode of action of several of these bacteriocins against
bioﬁlms. Further studies such as those conducted for gallidermin,
which showed transcriptional changes of atl and ic genes in S.
aureus bioﬁlms,53 and nisin and lacticin Q, which were shown to
elicit ATP efﬂux from cells in a bioﬁlm,46 could prove invaluable in
this regard. Furthermore, there is a lack of data concerning the
propensity for bacteriocin-resistance development in cells within a
bioﬁlm. The narrow-spectrum nature of certain bacteriocins would
render them ineffective against polymicrobial bioﬁlm commu-
nities, in which the speciﬁc composition of the bioﬁlm may be
largely unknown. Other potential obstacles include elucidating the
optimum dose of the bacteriocin required to eradicate bioﬁlms, as
doses required in therapeutic cases may not necessarily correlate
with in vitro ﬁndings. Finally, it may be the case that penetration
of certain high molecular weight bacteriocins, compared to
antibiotic counterparts, across the strata of the bioﬁlm may be
the rate-limiting factor governing the potential success of
bacteriocins in a bioﬁlm setting. A combination of innovative
strategies to prevent/retard the formation of a bioﬁlm are
warranted, examples of which include inhibiting quorum sensing
and communication within a bioﬁlm, in combination with potent
bacteriocins, to fully combat a bioﬁlm (Fig. 3).
Perhaps the most common, yet largely under-appreciated
bioﬁlm that exists in the human body is dental plaque, which
consists of bacteria embedded in a proteinaceous and
polysaccharide-rich matrix and is the causative agent of dental
caries and periodontal disease.88,170,171 It is interesting to note in
this regard that dental plaque is a very complex bioﬁlm consisting
of several streptococci and many of these streptococci actually
produce bacteriocins called mutacins in situ, which can control the
composition of the species that exist in the bioﬁlm, giving certain
strains a competitive advantage over others in the bioﬁlm.172–174
Indeed, a complex microbiome exists within an oral bioﬁlm and
the precise composition of this microbial community is likely to
determine the caries-causing potential of such a bioﬁlm. Depend-
ing on the nature and target speciﬁcity of any mutacins produced
in situ, it is possible that the cariogenic potential of dental plaque
can either be attenuated or in the worst-case scenario, even
enhanced by targeting strains associated with good oral health.
Fig. 3 Strategy map of anti-bioﬁlm activity of bacteriocins: Bioﬁlms can be formed by a variety of organisms on both biotic and abiotic
surfaces, including catheters, oral surfaces, wounds, food and stainless steel pipes. Bacteriocins could be utilised independently and in
combination with other antimicrobials, quorum sensing inhibitors, bioﬁlm degrading enzymes to inhibit bioﬁlm formation and/or eradicate
existing bioﬁlms. However, a number of bottlenecks and knowledge gaps must be addressed for this strategy to be successful. QS quorum
sensing, MTAD mixture of tetracycline, acid and doxycycline, LAE lauramide arginine ethyl ester, AMP antimicrobial peptide
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Nonetheless, a ‘probiotic’ Streptococcus strain producing mutacins
or other bacteriocins could potentially be harnessed to inhibit
other bioﬁlm-forming and caries-causing S. mutans strains. Despite
decades of research seeking antimicrobials which are effective at
targeting dental plaque however, it is widely accepted that the
most efﬁcient and cost-effective means to eradicate this particular
bioﬁlm is via simplistic mechanical debridement, by regularly
brushing, ﬂossing and scaling teeth.
Overall, minor differences in the 3D-structure of the polymeric
matrix and/or alterations in the physiology of bacteria that exist in
a bioﬁlm compared to a planktonic state are likely to contribute to
variations in sensitivity to bacteriocins and indeed other
antimicrobials. Thus, the ideal ratio of a bacteriocin mixed with
another stressor may play a key role in optimising the synergistic
effects that can be obtained against bioﬁlms or planktonic cells.
Furthermore, strategies which involve combining bacteriocins or
bioengineered derivatives thereof, with other antimicrobials such
as thiazolidinone derivatives, diterpenoids, epigallocatechin,
baicalin hydrate as well as other enzymes/agents that interfere
with molecular pathways involved in the formation of bioﬁlms
could prove to be successful.175 Since several of these target
bioﬁlms via non-microbicidal means, it is plausible that combina-
tions with a bacteriocin can be highly efﬁcacious both in terms of
inhibiting the bioﬁlm, as well as attenuating the likelihood of
development of resistance to the bacteriocin.176 Greater insights
into the precise structure-function properties of a bioﬁlm matrix as
well as the mode of action of several of these bacteriocins with
anti-bioﬁlm activity will have to be elucidated. Such insights are
likely to facilitate the successful treatment and eradication of
bioﬁlms. Thus, while bacteriocins have several beneﬁts as well as
shortcomings, this group of ribosomally synthesised antimicro-
bials may yet prove to be critical players in the ﬁght against
bioﬁlms, particularly when utilised in combination with other
existing anti-bioﬁlm agents.
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